Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
Adjuvants, Immunologic
Costa Rica
/ epidemiology
Double-Blind Method
Female
Human papillomavirus 16
/ immunology
Human papillomavirus 18
/ immunology
Humans
Papillomavirus Infections
/ epidemiology
Papillomavirus Vaccines
/ immunology
Treatment Outcome
Uterine Cervical Neoplasms
/ prevention & control
HPV
clearance
efficacy
progression
vaccination
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
20 05 2021
20 05 2021
Historique:
received:
18
05
2020
accepted:
01
09
2020
pubmed:
6
9
2020
medline:
12
2
2022
entrez:
5
9
2020
Statut:
ppublish
Résumé
Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.
Identifiants
pubmed: 32887990
pii: 5901687
doi: 10.1093/infdis/jiaa561
pmc: PMC8248553
doi:
Substances chimiques
Adjuvants, Immunologic
0
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1576-1581Subventions
Organisme : NCI NIH HHS
ID : N01CP11005
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Références
BMJ. 2019 Apr 3;365:l1161
pubmed: 30944092
Lancet Oncol. 2012 Jan;13(1):89-99
pubmed: 22075171
J Clin Pathol. 2005 Oct;58(10):1096-100
pubmed: 16189158
J Natl Cancer Inst. 2020 Aug 1;112(8):818-828
pubmed: 31697384
Papillomavirus Res. 2016 Dec;2:61-69
pubmed: 29074187
J Immunol. 2009 Nov 15;183(10):6186-97
pubmed: 19864596
Cancer Discov. 2011 Oct;1(5):408-19
pubmed: 22586631
Am J Obstet Gynecol. 2016 Aug;215(2):212.e1-212.e15
pubmed: 26892991
Lancet Oncol. 2012 Jan;13(1):100-10
pubmed: 22075170
Hum Vaccin. 2008 Nov-Dec;4(6):425-34
pubmed: 18948732
Expert Rev Vaccines. 2019 Mar;18(3):309-322
pubmed: 30739514
JNCI Cancer Spectr. 2019 Jan 07;2(4):pky045
pubmed: 31360870
Vaccine. 2006 Aug 14;24(33-34):5937-49
pubmed: 16828940
J Natl Cancer Inst. 2017 Jan 28;109(7):
pubmed: 28132019
PLoS One. 2019 Mar 4;14(3):e0212927
pubmed: 30830913